
| Disease Domain | Count |
|---|---|
| Neoplasms | 6 |
| Nervous System Diseases | 2 |
| Hemic and Lymphatic Diseases | 1 |
| Endocrinology and Metabolic Disease | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 10 |
| Synthetic peptide | 2 |
| Herbal medicine | 2 |
| CRISPR/Cas9 | 1 |
Target |
Mechanism LCN2 inhibitors [+2] |
Originator Org. |
Inactive Indication |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD4 modulators |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism αvβ3 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date17 Jun 2025 |
Sponsor / Collaborator West China Hospital [+10] |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date10 Oct 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
LM49 ( CD4 ) | Diabetic Nephropathies More | Phase 1 |
Hydroxysafflor Yellow A ( LCN2 x STAT3 x ZBP1 ) | Neuroinflammation More | Preclinical |
RGD-Ce/CD ( αvβ3 ) | Neoplasms More | Preclinical |
Inulin-type fructan CP-A ( Akt x EGFR x ERK ) | Colorectal Cancer More | Preclinical |
DA5-CH ( GIPR x GLP-1R ) | Alzheimer Disease More | Preclinical |





